| Titre : |
The clinical and économic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one -monthly formulation in the treatment of schizophrénia in France: A cost-utility study |
| Type de document : |
texte imprimé |
| Auteurs : |
Arteaga Duarte, C.H., Auteur ; P. Guillon, Auteur ; E. Fakra, Auteur |
| Année de publication : |
2019 |
| Article en page(s) : |
p. 459-467 |
| Langues : |
Anglais (eng) |
| Catégories : |
[Thesaurus n°1] France
[Thesaurus n°1] Pharmacologie:Antipsychotiques
[Thesaurus n°1] Troubles psychotiques:Schizophrénie
|
| Mots-clés : |
paliperidone palmitate coût efficacité |
| Résumé : |
Schizophrenia entails a considerable humanistic and economic burden. Improved treatment continuity to antipsychotic therapy is paramount to reduce the risk of relapse. The novel three-monthly paliperidone palmitate treatment (PP3M) offers the longest dosing interval currently available in France. This study assesses its cost-effectiveness, versus the currently available one-monthly long-acting treatment (PP1M) in French schizophrenic patients. |
| Permalink : |
https://ch-poitiers.fr/opac_css/index.php?lvl=notice_display&id=106997 |
The clinical and économic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one -monthly formulation in the treatment of schizophrénia in France: A cost-utility study in L'encéphale, n°6 (Décembre 2019 Vol. 45) 
